Holen Sie sich die Stockscreener-App
0.67
3.67%
-0.0255
Handel nachbörslich:
.68
0.01
+1.49%
Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Has Average Target Price of $3.90 - MarketBeat
Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia’s Rare Kidney Pipeline at ASN Kidney Week 2026 - Yahoo Finance
Akebia Therapeutics, Inc. (AKBA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
A new hire's right to buy 8,400 Akebia shares phases in over four years, if they stay. - Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Long term debt to total equity ratio of Akebia Therapeutics, Inc. – HAN:AX9 - tradingview.com
Akebia Therapeutics, Inc. Revenue Breakdown – MUN:AX9 - TradingView
Akebia Therapeutics to Report Third Quarter 2023 Financial Results and Discuss Recent Business Highlights - Lelezard
Akebia Therapeutics, Inc. $AKBA Position Reduced by State Street Corp - MarketBeat
AKBA Shares Rise On Clinical Pipeline Optimism As Anemia Drug Gains Traction - Stocktwits
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Exploring A 337% Potential Upside - DirectorsTalk Interviews
Akebia Therapeutics Doses First Patient in Phase 2 Ebribafusp Trial - marketscreener.com
One trial, three rare kidney diseases: Akebia doses its first patient - Stock Titan
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases - Yahoo Finance
Akebia Therapeutics Announces First Patient Dosed in Phase - globenewswire.com
Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
Akebia Therapeutics (NasdaqCM:AKBA) Stock Forecast & Analyst Predictions - simplywall.st
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by Wall Street Zen to Hold Rating - marketbeat.com
AKBA Initiates Coverage On WestPark Capital -- Rating Set to Buy - GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from Analysts at Westpark Capital - marketbeat.com
BlackRock Inc. Buys Shares of 19,986,374 Akebia Therapeutics, Inc. $AKBA - marketbeat.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - marketscreener.com
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston - Yahoo Finance
Nantahala Capital Management LLC Takes Position in Akebia Therapeutics, Inc. $AKBA - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Stock Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Akebia (AKBA) Market: Slides 1.39% to $0.91 for the Current Session; Key Range: the Near-Term Reference Band Stretches From $0.86 to $0.96 on the DayRTH Profile - vinanet.vn
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of "Hold" by Analysts - MarketBeat
Akebia Therapeutics, Inc. Revenue Breakdown – NASDAQ:AKBA - TradingView
Piper Sandler Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Beats Estimates by 33.18%Return On Equity - vinanet.vn
Akebia Therapeutics CEO John P. Butler Exercises 350,000 Stock Options at $0.63 Each - Kalkine Media
Weekly Recap: Vafseo sales surge and ebribafusp Phase 2 trial start - TradingView
Akebia Therapeutics, Inc. $AKBA Shares Sold by Renaissance Technologies LLC - MarketBeat
HC Wainwright Has Negative Outlook of AKBA FY2026 Earnings - MarketBeat
Akebia Therapeutics (AKBA) AGM 2026 Summary - Quartr
Akebia Therapeutics Price Target Announced at $1.00/Share by Leerink Partners - Moomoo
Akebia Therapeutics Inc (AKBA) Stock News Today - TradingKey
Akebia Therapeutics Inc (AKBA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Leerink Partners to "Market Perform" - MarketBeat
Akebia Therapeutics Inc (AKBA:UR): Stock Price, Quote and News - BNN Bloomberg
Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Analyzing a 340% Potential Upside Amid Healthcare Innovation - DirectorsTalk Interviews
AKBA Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 55.5% EPS SurpriseEarnings Season Outlook - vinanet.vn
H.C. Wainwright Maintains Akebia Therapeutics(AKBA.US) With Buy Rating, Maintains Target Price $6 - Moomoo
6.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):